Scancell Holdings (GB:SCLP) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Scancell Holdings Plc has successfully raised £10.3 million through an oversubscribed placing, which attracted substantial interest from existing and new healthcare specialist investors. The funds will support the development of its cancer vaccine, SCIB1, and its next-generation counterpart, iSCIB1+, as the company strives to advance its clinical trials for treating advanced melanoma. This financial boost is set to extend Scancell’s cash runway into the second half of 2026, signaling robust investor confidence in its innovative immunotherapy solutions.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue